Optimised Treatment for Hypertension Trial

NANot yet recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

August 28, 2025

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2026

Conditions
Hypertension
Interventions
OTHER

Fire and forget

Evidence informed prescription of BP lowering drugs based on the average observed blood pressure (BP) reduction and risk of treatment discontinuation due to adverse effects in double-blind placebo-controlled randomised clinical trials. Clinicians will prescribe BP treatment regimen using generic, established BP lowering medications that will be expected to achieve at least 80% of future systolic BP values under 130 mmHg. Treatment will be delivered remotely through telehealth consultation. Participants will be asked to avoid routine BP measurements after treatment is commenced to avoid misleading chance fluctuations in BP before 12 weeks. Adverse events will be monitored remotely, and treatments can be adjusted according to adverse events but not according to BP measurements

OTHER

Usual care with more intensive BP monitoring

"Participants will follow-up with their usual general practitioner, who will treat participants BP according to local practice guidelines. General practitioners will have access to the same BP lowering medications as the fire and forget treatment group. Participants will continue to monitor their BP throughout the 12 week period through home BP monitoring with optional 24 hour ambulatory BP monitoring. Participants will maintain a BP diary and present their BP results to their treating physician."

Trial Locations (1)

2000

The George Institute for Global Health, Sydney

All Listed Sponsors
lead

The George Institute

OTHER

NCT06935760 - Optimised Treatment for Hypertension Trial | Biotech Hunter | Biotech Hunter